The von Willebrand Inhibitor ARC1779 Reduces Cerebral Embolization After Carotid Endarterectomy: A Randomized Trial

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Stroke

• Publication date

  2011-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/STROKEAHA.111.616649PMID 21700934
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis

  2010cited by this paper
• Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial.

  2010cited by this paper
• The aptamer ARC1779 is a potent and specific inhibitor of von willebrand factor mediated ex vivo platelet function in acute myocardial infarction

  2009cited by this paper
• Deficiency of von Willebrand factor protects mice from ischemic stroke.

  2009cited by this paper
• Doppler Embolic Signals in Cerebrovascular Disease and Prediction of Stroke Risk: A Systematic Review and Meta-Analysis

  2009cited by this paper
• Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.

  2007cited by this paper
• First-inHuman Evaluation of Anti – von Willebrand Factor Therapeutic Aptamer ARC 1779 in Healthy Volunteers

  2007cited by this paper
• First-in-Human Evaluation of Anti–von Willebrand Factor Therapeutic Aptamer ARC1779 in Healthy Volunteers

  2007cited by this paper
• Recent advances in management of transient ischaemic attacks and minor ischaemic strokes.

  2006cited by this paper
• Aptamer therapeutics advance.

  2006cited by this paper
• Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.

  2006cited by this paper
• Dual Antiplatelet Therapy With Clopidogrel and Aspirin in Symptomatic Carotid Stenosis Evaluated Using Doppler Embolic Signal Detection: The Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) Trial

  2005cited by this paper
• Asymptomatic Embolization Detected by Doppler Ultrasound Predicts Stroke Risk in Symptomatic Carotid Artery Stenosis

  2005cited by this paper
• Beneficial Effects of Clopidogrel Combined With Aspirin in Reducing Cerebral Emboli in Patients Undergoing Carotid Endarterectomy

  2004cited by this paper
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

  2002cited by this paper
• Switching off Embolization From Symptomatic Carotid Plaque Using S-Nitrosoglutathione

  2002cited by this paper
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

  2002cited by this paper
• l-Arginine and S-Nitrosoglutathione Reduce Embolization in Humans

  2001cited by this paper
• Consensus on microembolus detection by TCD. International Consensus Group on Microembolus Detection.

  1998cited by this paper
• Transcranial Doppler detected cerebral microembolism following carotid endarterectomy.

  1998cited by this paper
• Consensus on Microembolus Detection by TCD

  1998cited by this paper
• Transcranial Doppler detected cerebral microembolism following carotid endarterectomy. High microembolic signal loads predict postoperative cerebral ischaemia.

  1997cited by this paper
• Use of a decibel threshold in detecting Doppler embolic signals.

  1997cited by this paper
• Differentiation Between Different Pathological Cerebral Embolic Materials Using Transcranial Doppler in an In Vitro Model

  1993cited by this paper
• Commentary on Andersen and Gill's "Cox's Regression Model for Counting Processes: A Large Sample Study"

  1982cited by this paper

• Reinventing the wheel in ischemic stroke: Novel aspects in ADAMTS13 and von Willebrand axis.

  2026cites this paper
• Emerging role of nucleic acid aptamers in sepsis-induced coagulopathy: Future perspectives in diagnostics and therapeutics.

  2026cites this paper
• RNA aptamer-mediated RNA nanotechnology for potential treatment of cardiopulmonary diseases.

  2025cites this paper
• Early detection of Parkinson's disease via aptamer-CRISPR platform.

  2025cites this paper
• Von Willebrand Factor as a Therapeutic Target in Thrombotic Disorders

  2025cites this paper
• Evaluating caplacizumab's potential to mitigate thrombosis risk in aortic valve stenosis: a microfluidic and computational approach.

  2025cites this paper
• The prospective approach for aptamers applied in the treatment and molecular diagnostics of ischemic stroke

  2025cites this paper
• Antibody and aptamer-based therapies for osteoarthritis: Application of antibodies and promise of aptamers

  2025cites this paper
• Emerging Targets, Novel Directions, and Innovative Approaches in Thrombosis Therapy

  2025cites this paper
• Pharmacologie des médicaments antiplaquettaires

  2024cites this paper
• ISCHAEMIC STROKE, THROMBOEMBOLISM AND CLOT STRUCTURE.

  2024cites this paper
• Von Willebrand factor targeted thrombolysis in canine basilar artery occlusion

  2024cites this paper
• Médicaments antiplaquettaires actuels et futurs

  2023cites this paper
• Diagnostic and Therapeutic Aptamers

  2023cites this paper
• Chemical Modifications for a Next Generation of Nucleic Acid Aptamers

  2022cites this paper
• Aptamers: Potential Diagnostic and Therapeutic Agents for Blood Diseases

  2022cites this paper
• Sex differences in thrombosis as it affects acute ischemic stroke.

  2022cites this paper
• Aptamers Regulating the Hemostasis System

  2022cites this paper
• Von Willebrand factor in diagnostics and treatment of cardiovascular disease: Recent advances and prospects

  2022cites this paper
• Novel Antithrombotic Agents in Ischemic Cardiovascular Disease: Progress in the Search for the Optimal Treatment

  2022cites this paper
• Novel approaches to antiplatelet therapy.

  2022cites this paper
• Aptamer-based applications for cardiovascular disease

  2022cites this paper
• Regulation of VWF (Von Willebrand Factor) in Inflammatory Thrombosis

  2022cites this paper
• High on‐treatment platelet reactivity is associated with poor outcomes after ischemic stroke: A meta‐analysis

  2022cites this paper
• Factors Associated with Platelet Activation-Recent Pharmaceutical Approaches

  2022cites this paper
• Overview of the Therapeutic Potential of Aptamers Targeting Coagulation Factors

  2021cites this paper
• Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases

  2021cites this paper
• The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial

  2021cites this paper
• RNA Therapeutics - Research and Clinical Advancements

  2021cites this paper
• Aptamers for Thrombotic Diseases

  2021cites this paper
• Targeting von Willebrand factor in liver diseases: A novel therapeutic strategy?

  2021cites this paper
• Drug delivery systems for cardiovascular ailments

  2021cites this paper
• Nanoparticle delivery of cardioprotective therapies.

  2020cites this paper
• Identification and Engineering of Aptamers for Theranostic Application in Human Health and Disorders

  2020cites this paper
• Platelet Inhibition in Acute Coronary Syndrome and Percutaneous Coronary Intervention: Insights from the Past and Present

  2020cites this paper
• Novel Antiplatelet Agents in Cardiovascular Disease

  2020cites this paper
• The development and characterization of a long acting anti‐thrombotic von Willebrand factor (VWF) aptamer

  2020cites this paper
• Shear Stress-Induced Activation of von Willebrand Factor and Cardiovascular Pathology

  2020cites this paper
• von Willebrand Factor Antigen, von Willebrand Factor Propeptide, and ADAMTS13 in Carotid Stenosis and Their Relationship with Cerebral Microemboli

  2020cites this paper
• Antithrombotic Therapy: Prevention and Treatment of Atherosclerosis and Atherothrombosis.

  2020cites this paper
• von Willebrand Factor Predicts Mortality in ACS Patients Treated with Potent P2Y12 Antagonists and is Inhibited by Aptamer BT200 Ex Vivo

  2020cites this paper
• The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxin

  2020cites this paper
• Novel antiplatelet targets in the treatment of acute coronary syndromes

  2020cites this paper
• Therapeutic Aptamers: Evolving to Find Their Clinical Niche.

  2020cites this paper
• Therapeutic strategies for thrombosis: new targets and approaches

  2020cites this paper
• Antithrombotic effect of SP‐8008, a benzoic acid derivative, through the selective inhibition of shear stress‐induced platelet aggregation

  2020influential citation
• Emerging mechanisms to modulate VWF release from endothelial cells.

  2020cites this paper
• A new drug for an old concept: aptamer to von Willebrand factor for prevention of arterial and microvascular thrombosis

  2020cites this paper
• Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels.

  2019cites this paper
• Nucleic Acid Therapies for Ischemic Stroke

  2019cites this paper
• Novel Antiplatelet Therapies

  2019cites this paper
• ATVB in Focus From Cells to the Clinic : Progress in the Development of Novel Therapeutics for ATVB Diseases

  2019cites this paper
• Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic.

  2019cites this paper
• Shear-Dependent Platelet Aggregation: Mechanisms and Therapeutic Opportunities

  2019cites this paper
• Biomechanical thrombosis: the dark side of force and dawn of mechano-medicine

  2019cites this paper
• Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacy☆

  2019cites this paper
• Short-Acting Anti-VWF (von Willebrand Factor) Aptamer Improves the Recovery, Survival, and Hemostatic Functions of Refrigerated Platelets.

  2019cites this paper
• Translational Implications of Platelets as Vascular First Responders

  2018cites this paper
• Current and future antiplatelet therapies: emphasis on preserving haemostasis

  2018cites this paper
• The search for new antithrombotic mechanisms and therapies that may spare hemostasis.

  2018cites this paper
• Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence

  2018cites this paper
• Humanized GPIbα-von Willebrand factor interaction in the mouse.

  2018cites this paper
• Thromboinflammation beim ischämischen Schlaganfall – pathophysiologisches Konzept und translationale Relevanz

  2018cites this paper
• Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target.

  2017cites this paper
• Aptamers as Therapeutics.

  2017cites this paper
• Inhibitors of Platelet Adhesion to VWF and Collagen

  2017cites this paper
• The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy

  2017cites this paper
• The chimeric monoclonal antibody MHCSZ-123 against human von Willebrand factor A3 domain inhibits high-shear arterial thrombosis in a Rhesus monkey model

  2017cites this paper
• von Willebrand Factor and Venous Thromboembolism: Pathogenic Link and Therapeutic Implications

  2017cites this paper
• Oligonucleotide‐based pharmaceuticals: Non‐clinical and clinical safety signals and non‐clinical testing strategies

  2017cites this paper
• Endothelial cell markers from clinician's perspective.

  2017cites this paper
• DNA-aptamers raised against AGEs as a blocker of various aging-related disorders

  2016cites this paper
• Combined administration of the GPVI-Fc fusion protein Revacept with low-dose thrombolysis in the treatment of stroke

  2016cites this paper
• RNA therapeutics – The potential treatment for myocardial infarction

  2016cites this paper
• Thromboinflammation in Stroke Brain Damage

  2016cites this paper
• Translation and Clinical Development of Antithrombotic Aptamers

  2016cites this paper
• From selection hits to clinical leads: progress in aptamer discovery

  2016cites this paper
• 52 – Antithrombotic Therapy for Treatment of Acute Ischemic Stroke

  2016cites this paper
• Development of Antithrombotic Aptamers: From Recognizing Elements to Drugs.

  2016cites this paper
• Antiplatelet drugs: which targets for which treatments?

  2015cites this paper
• Modulation of the Coagulation Cascade Using Aptamers

  2015cites this paper
• Activated-platelet targeting of CD39 as a potential way forward

  2015cites this paper
• The modulation of coagulation by aptamers: an up-to-date review

  2015cites this paper
• [Anti-platelets without a bleeding risk: novel targets and strategies].

  2015cites this paper
• DNA Aptamers in the Diagnosis and Treatment of Human Diseases

  2015cites this paper
• Von Willebrand factor is reversibly decreased during torpor in 13-lined ground squirrels

  2015cites this paper
• Prospective validation study of transorbital Doppler ultrasound imaging for the detection of transient cerebral microemboli

  2014cites this paper
• Development of aptamer oligonucleotides as anticoagulants and antithrombotics for cardiovascular diseases: current status.

  2014cites this paper
• Aptamers as Promising Molecular Recognition Elements for Diagnostics and Therapeutics in the Central Nervous System

  2014cites this paper
• Etude du rôle des étapes initiales d'adhérence des plaquettes sanguines et du flux pulsatile dans l'agrégation plaquettaire

  2014cites this paper
• Platelet Receptors and Drug Targets: PAR1, Collagen, vWF, Thromboxane, and Other Novel Targets

  2014cites this paper
• Aptamer-functionalized Hydrogels for the Programmable Release of Growth Factors

  2014cites this paper
• Synergistic Effect of AJW200, a von Willebrand Factor Neutralizing Antibody with Low Dose (0.9 mg/mg) Thrombolytic Therapy Following Embolic Stroke in Rabbits.

  2013cites this paper
• The Oxidative Modification of Von Willebrand Factor Is Associated with Thrombotic Angiopathies in Diabetes Mellitus

  2013cites this paper
• Targeting Platelet GPIb&bgr; Reduces Platelet Adhesion, GPIb Signaling and Thrombin Generation and Prevents Arterial Thrombosis

  2013cites this paper
• Novel antiplatelet drugs in clinical development

  2013cites this paper
• Chapter 58 – Novel Antiplatelet Therapies

  2013cites this paper
• Interaction Between vWF Levels and Aspirin Resistance in Ischemic Stroke Patients

  2013cites this paper
• DNA Aptamer Raised Against AGEs Blocks the Progression of Experimental Diabetic Nephropathy

  2013cites this paper
• No risk, no benefit: still true for antithrombotic stroke treatments?

  2013cites this paper